Entera Bio Ltd
Company Profile
Business description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Contact
Minrav Building - Fifth Floor
Kiryat Hadassah
Jerusalem9112002
ISRT: +972 25327151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
21
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,849.60 | 7.00 | -0.08% |
| CAC 40 | 8,126.33 | 43.76 | -0.54% |
| DAX 40 | 23,588.99 | 287.56 | -1.20% |
| Dow JONES (US) | 47,055.31 | 401.91 | -0.85% |
| FTSE 100 | 9,687.94 | 10.43 | -0.11% |
| HKSE | 26,384.28 | 188.18 | -0.71% |
| NASDAQ | 22,883.94 | 16.65 | -0.07% |
| Nikkei 225 | 50,323.91 | 52.62 | -0.10% |
| NZX 50 Index | 13,459.15 | 5.31 | -0.04% |
| S&P 500 | 6,723.72 | 10.39 | -0.15% |
| S&P/ASX 200 | 8,571.80 | 7.00 | -0.08% |
| SSE Composite Index | 3,972.03 | 18.46 | -0.46% |